Curcumin (BRN 2306965, CCRIS 3257, NSC 32982, NSC 687842, CI 75300)

Anti-cancer compound. Interferes with multiple cell signaling pathways, including cell cycle (cyclin D1 and cyclin E), apoptosis (activation of caspases and down-regulation of anti-apoptotic gene products), proliferation (HER-2, EGFR and AP-1), survival (PI3K/AKT pathway), invasion (MMP-9 and adhesion molecules), angiogenesis (VEGF), metastasis (CXCR-4) and inflammation (NF-kappaB, TNF, IL-6, IL-1, COX-2 and 5-LOX). Anti-angiogenic. Anti-metastatic. Anti-invasive. Chemopreventive. Hedgehog signaling (Hh) modulator. Downregulates Shh and Gli1. \nAntioxidant. Anti-inflammatory. Potent inhibitor of NF-kappaB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS; NOSII). Downregulates the expression of various proinflammatory cytokines including TNF, IL-1, IL-2, IL-6, IL-8, IL-12 and chemokines. \n\nPotent immunomodulator. Modulates several key transcription factors. Down-regulate transcription factors NF-kappaB, AP-1 and Egr-1. Down-regulates the expression of COX-2, LOX, NOS, MMP-9, uPA, TNF, chemokines, cell surface adhesion molecules and cyclin D1. Down-regulate growth factor receptors (such as EGFR and HER2) and inhibits the activity of c-Jun N-terminal kinase, protein tyrosine kinases and protein serine/threonine kinases. \nNeuroprotective. Anti-amyloid activity. \n\nCardioprotective. p300/CBP-HAT inhibitor. Regulates lipid metabolism and downregulates obesity. Activates peroxisome proliferator-activated receptor-gamma (PPARgamma) and Nrf2 cell-signaling pathways. Antiviral, antibacterial, antifungal. Epigenetic agent. Interacts with histone deacetylases (HDACs), histone acetyltransferases (HATs), DNA methyltransferase I and microRNAs. \n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: -20 degrees C\nStable for at least 2 years after receipt when stored at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

044714

Size

10mg

Purity

>98% (HPLC)

References

Product Reference: \nAnticancer potential of curcumin: preclinical and clinical studies: B.B. Aggarwal, et al.; Anticancer Res. 23, 363 (2003) (Review)?\nCurcumin: the story so far: R.A. Sharma, et al.; Eur. J. Cancer 41, 1955 (2005) (Review)?\nCurcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases: S. Bengmark; JPEN J. Parenter. Enteral. Nutr. 30, 45 (2006) (Review)?\nMultiple biological activities of curcumin: a short review: R.K. Maheshwari, et al.; Life Sci. 78, 2081 (2006) (Review)?\n\"Spicing up\" of the immune system by curcumin: G.C. Jagetia & B.B. Aggarwal; J. Clin. Immunol. 27, 19 (2007) (Review)?\nCurcumin: the Indian solid gold: B.B. Aggarwal, et al.; Adv. Exp. Med. Biol. 595, 1 (2007) (Review)?\nAntioxidant and anti-inflammatory properties of curcumin: V.P. Menon & A.R. Sudheer; Adv. Exp. Med. Biol. 595, 105 (2007) (Review)?\nModulation of transcription factors by curcumin: S. Shishodia, et al.; Adv. Exp. Med. Biol. 595, 127 (2007) (Review)?\nAntitumor, anti-invasion, and antimetastatic effects of curcumin: G. Kuttan, et al.; Adv. Exp. Med. Biol. 595, 173 (2007) (Review)?\nCurcumin as an inhibitor of angiogenesis: S.S. Bhandarkar & J.L. Arbiser; Adv. Exp. Med. Biol. 595, 185 (2007) (Review)?\nNeuroprotective effects of curcumin: G.M. Cole, et al.; Adv. Exp. Med. Biol. 595, 197 (2007) (Review)?\nImmunomodulation by curcumin: S.C. Gautam, et al.; Adv. Exp. Med. Biol. 595, 321 (2007) (Review)?\nCurcumin and cancer: an \"old-age\" disease with an \"age-old\" solution: P. Anand, et al.; Cancer Lett. 267, 133 (2008) (Review)?\nPotential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases: B.B. Aggarwal & K.B. Harikumar; Int. J. Biochem. Cell Biol. 41, 40 (2009) (Review)?\nThe protective role of curcumin in cardiovascular diseases: W. Wongcharoen & A. Phrommintikul; Int. J. Cardiol. 133, 145 (2009) (Review)?\nREVIEW: Curcumin and Alzheimer's disease: T. Hamaguchi, et al.; CNS Neurosci. Ther. 16, 285 (2010) (Review)?\nTargeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals: B.B. Aggarwal; Annu. Rev. Nutr. 30, 173 (2010) (Review)?\nDevelopment of curcumin as an epigenetic agent: S. Fu & R. Kurzrock; Cancer 116, 4670 (2010) (Review)?\nThe role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer: F.H. Sarkar, et al.; Cancer Metastasis Rev. 29, 383 (2010) (Review)?\nCurcumin and obesity: evidence and mechanisms: L. Alappat & A.B. Awad; Nutr. Rev. 68, 729 (2010) (Review)?\nCurcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment: P. Basnet & N. Skalko-Basnet; Molecules 16, 4567 (2011) (Review)?\nCurcumin: a potential neuroprotective agent in Parkinson's disease: R.B. Mythri & M.M. Bharath; Curr. Pharm. Des. 18, 91 (2012) (Review)?\n

Alternative Names

BRN 2306965, CCRIS 3257, NSC 32982, NSC 687842, CI 75300